Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells

Journal of Medical Genetics

Volumn 44, Issue 1, 2007, Pages 75-80

  Alazzouzi, Hafid ^a   Suriano, Gianpaolo ^b   Guerra, Angel ^a   Plaja, Alberto ^a   Espín, Eloi ^a   Armengol, Manel ^a   Alhopuro, Pia ^c   Velho, Sergia ^b   Shinomura, Yasuhisa ^d   González Aguilera, Juan José ^e   Yamamoto, Hiroyuki ^d   Aaltonen, Lauri A ^c   Moreno, Victor ^f   Capellà, Gabriel ^f   Peinado, Miguel Angel ^g   Seruca, Raquel ^b   Arango, Diego ^a   Schwartz Jr , Simó ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF HELSINKI   (Finland)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^g BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ARTICLE; CANCER RECURRENCE; CANCER RISK; COLORECTAL CANCER; GENE MUTATION; GENE SEQUENCE; GENETIC PREDISPOSITION; GENETIC RISK; HOMOZYGOTE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM;

AGE OF ONSET; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; GENES, P53; HOMOZYGOTE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS;

EID: 33846443195     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2006.042572     Document Type: Article

References (18)

1. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002;14:86-91.
2. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002;3:101-28.
3. Tachibana M, Kawamata H, Fujimori T, Omotehara F, Horiuchi H, Ohkura Y, Igarashi S, Kofake K, Kubota K. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of p53-associated factors p14ARF, p33ING1, p21WAF and MDM2. Int J Oncol 2004;25:913-20.
4. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003;1:1001-8.
5. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55:96-107.
6. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 1997;11:1974- 86.
7. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
8. Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res 2004;2:1-8.
9. Abdel-Fattah G, Yoffe B, Krishnan B, Khaoustov V, Itani K. MDM2/p53 protein expression in the development of colorectal adenocarcinoma. J Gastrointest Surg 2000;4:109-14.
10. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 1998;95:15608-12.
11. Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol Med 2002;8:185-99.
12. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang S, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
13. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J. A chromatin associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 2005;280:26776-87.
14. Alhopuro P, Ylisaukko-oja SK, Koskinen WJ, Bono P, Arola J, Järvinen HJ, Mecklin J-P, Atula T, Kontio R, Mäkitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA. The MDM2 promoter polymorphism SNP309T>G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and Neck. J Med Genet 2005;42:694-8.
15. Sotamaa K, Liyanarachchi S, Mecklin JP, Järvinen H, Aaltonen LA, Peltomäki P, de la Chapelle A. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005;11:6840-4.
16. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava SA. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
17. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D'Andrea E, Nitti D, Amadori A, Bertorelle R. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285- 8.
18. Varley JM, Thorncroft M, McGrown G, Appleby J, Kelsey AM, Tricker KJ, Evans DG, Birch JM. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 pene. Oncogene 1997;14:865-71.